Isomorphic Labs, an AI drug discovery startup founded by Demis Hassabis, has raised $5 billion in Series C funding. Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz and Alphabet also investing.
Hassabis left his role as CEO of Google DeepMind three-and-a-half months before this funding announcement. He has led Isomorphic since the company spun out of DeepMind in 2021.
The company plans to use the new capital to build foundational biology models, deepen disease understanding, and move its first therapeutic programs toward clinical trials. Isomorphic is developing a proprietary drug design engine and therapeutic candidate pipeline powered by AI.
"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," Hassabis said.
Isomorphic raised $2.1 billion in a Series B round in May. Drug discovery startups have raised $23.2 billion in 2026 overall, according to deal-counting platform Dealroom, a record figure. Anthropic launched an AI drug discovery program in June, while OpenAI partnered with Novo Nordisk in April.